Evidence mapPaperPMID 21518979Full record

ArticleCirculation2011

Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins?

James K Liao

Abstract readCommentEditorial
In one paragraph

Article in Circulation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Widespread transposable element dysregulation in human aging brains with Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Pyridine Dinucleotides from Molecules to Man.Antioxidants & redox signaling · 2018
    Review
  10. Review
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

James K Liao

Funding

LIPOPROTEINS EFFECTS ON G PROTEIN FUNCTIONR01HL052233 · BRIGHAM AND WOMEN'S HOSPITAL · 1995 to 2004
$1.7M
NHLBI NIH HHS HL052233NHLBI NIH HHS R01 HL052233NHLBI NIH HHS R01 HL080187NIDDK NIH HHS R01 DK085006NINDS NIH HHS R01 NS070001
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anticholesteremic AgentsCardiovascular DiseasesFarnesyl-Diphosphate FarnesyltransferaseHumansHydroxymethylglutaryl-CoA Reductase InhibitorsOxazepinesPiperidines1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acidAnticholesteremic AgentsFarnesyl-Diphosphate FarnesyltransferaseHydroxymethylglutaryl-CoA Reductase InhibitorsOxazepinesPiperidines

Identifiers

PMID21518979
PMCPMC3807098

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.